RVPH

Reviva Pharmaceuticals Holdings

RVPH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RVPH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

May 13

Reviva Pharmaceuticals Holdings, Inc. ($RVPH) will be delisted from Nasdaq and will begin trading on OTCQB on May 14.
The company has 7 active Phase 4 trials for its drug "d", but there is no assurance of maintaining compliance.
The stock price has declined significantly, from $0.7900 to $0.3448 (-56.4%), ahead of the delisting.

Generated by AI

Sentiment

Of the messages about RVPH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	80% new	78.58% -8.63
Bearish	0%	0%	20% -80	21.42% +8.63

Bullish· Mar 19

Reviva Pharmaceuticals Holdings, Inc. (RVPH) has a significant amount of shares issued with warrants, potentially increasing its float by four times.
The company has recently received a substantial amount of cash, which will be put to good use, and is likely to receive another split approved, similar to Mullen Automotive's 20 splits.
The stock has shown a significant price increase, with one user selling their shares at $85 after buying them at $0.67, and another user believing the upside looks amazing due to a positive phase 3 study and $10 million raised.

Bearish· May 13

The company's stock price has declined significantly, with one post mentioning a 50% drop in price.
The company is facing delisting from the Nasdaq and will begin trading on the OTCQB, which may result in lower liquidity and higher fees.
The company's management has been criticized, with one post stating that the CEO made "the worst possible decision at every turn" and another post calling the CEO a "POS" and predicting lawsuits.

Generated by AI

Topics

Of the messages about RVPH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	3.23%
Announcements	—	—	100%	32.65%
Controversies	—	—	0%	1.32%
Earnings	—	—	0%	-0.08%
Macro	—	—	0%	49.66%
Technical Analysis	—	—	0%	13.22%

Mar 19

Reviva Pharmaceuticals Holdings, Inc. ($RVPH) announced the pricing of a $10 million public offering of 6,666,667 shares at $1.50 per share.
The company will use the net proceeds of approximately $9 million for research and other corporate purposes, including the launch of the RECOVER-2 trial in schizophrenia.
The public offering includes warrants with a 5-year duration and an exercise price of $1.50, with funds also allocated for general corporate needs.

Generated by AI

Community

Of the messages about RVPH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	70%	13.32%
Newcomers	—	—	30%	86.68%

Regulars· Mar 19

$RVPH is trading lower after the company announced the pricing of its $10 million public offering of 6,666,667 shares at $1.50 per share.
The public offering will raise approximately $10 million, with net proceeds of about $9 million for research and corporate purposes.
Reviva Pharmaceuticals plans to use the funds to launch the RECOVER-2 trial for schizophrenia and other corporate purposes, with the warrants exercisable at $1.50 for a 5-year duration.

Newcomers· Mar 19

Reviva Pharmaceuticals Holdings, Inc. has announced a public offering of $10 million, with a total of 666,667 shares of common stock sold at $1.50 per share.
The company will also issue Series G and H warrants as part of the public offering.
Reviva Pharmaceuticals' public offering is expected to provide the company with additional funds to support its late-stage pharmaceutical development.

Generated by AI

NEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of CERo Therapeutics Holdings, Inc. CERo Therapeutics Holdings, Inc.’s securities were suspended on October 31, 2025 and have not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the ordinary shares, units, and rights of Bowen Acquisition Corp. Bowen Acquisition Corp’s securities were suspended on November 3, 2025 and have not trad

2mo agoYahoo Finance

Also Discussed

Investors talking about RVPH also mention

#	Name	Attention
1	VIVK - Vivakor, Inc.	——
2	374Water Inc.SCWO	0.01%+0.01
3	Femasys Inc.FEMY	0%+0
4	Dragonfly Energy Holdings Corp.DFLI	0%0
5	Aligos Therapeutics, Inc.ALGS	0%new
6	Mobix Labs, Inc. Class A Common StockMOBX	0%0
7	AtlasClear Holdings, Inc.ATCH	0.01%0
8	Calidi Biotherapeutics, Inc.CLDI	0%0
9	KRTX - Karuna Therapeutics, Inc.	——
10	BioAtla Inc.BCAB	0%new